Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: Role of HMGB1/TLR4/IL-33 axis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 10, 2015, Pages 2075-2085

  Tao, Aibin ^a,b,e   Song, Jia ^a   Lan, Ting ^b,e   Xu, Xuemei ^b   Kvietys, Peter ^d   Kao, Raymond ^b,c,e   Martin, Claudio ^b,c,e   Rui, Tao ^a,b,c,e  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d ALFAISAL UNIVERSITY   (Saudi Arabia)

^e WESTERN UNIVERSITY   (Canada)

Author keywords

Diabetes mellitus; HMGB1; IL 33; Myocardial fibrosis; TLR4

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 33; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CELL INTERACTION; COCULTURE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; HEART FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOFLUORESCENCE; MALE; MOUSE; NEWBORN; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING;

MURINAE; MUS; RODENTIA;

EID: 84938235165     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.07.015     Document Type: Article

References (47)

1. Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 2014, 142:375-415.
2. Aneja A., Tang W.H., Bansilal S., Garcia M.J., Farkouh M.E. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med. 2008, 121:748-757.
3. Boudina S., Abel E.D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 2010, 11:31-39.
4. Zhang Y., Babcock S.A., Hu N., Maris J.R., Wang H., Ren J. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function. BMC Med. 2012, 10:40.
5. Bhatt N.M., Aon M.A., Tocchetti C.G., Shen X., Dey S., Ramirez-Correa G., O'Rourke B., Gao W.D., Cortassa S. Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose. Am. J. Physiol. Heart Circ. Physiol. 2015, 308:H291-H302.
6. Ward M.L., Crossman D.J. Mechanisms underlying the impaired contractility of diabetic cardiomyopathy. World J. Cardiol. 2014, 6:577-584.
7. Amaral N., Okonko D.O. Metabolic abnormalities of the heart in type II diabetes. Diab. Vasc. Dis. Res. 2015, 12:239-248.
8. Kumar S., Kain V., Sitasawad S.L. High glucose-induced Ca2+ overload and oxidative stress contribute to apoptosis of cardiac cells through mitochondrial dependent and independent pathways. Biochim. Biophys. Acta 2012, 1820:907-920.
9. Law B., Fowlkes V., Goldsmith J.G., Carver W., Goldsmith E.C. Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc. Microanal. 2012, 18:22-34.
10. Mewton N., Liu C.Y., Croisille P., Bluemke D., Lima J.A. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011, 57:891-903.
11. Jellis C., Wright J., Kennedy D., Sacre J., Jenkins C., Haluska B., Martin J., Fenwick J., Marwick T.H. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ. Cardiovasc. Imaging 2011, 4:693-702.
12. Zhao J., Randive R., Stewart J.A. Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. World J. Diabetes 2014, 5:860-867.
13. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 2003, 21:3-12.
14. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123:255-278.
15. Sedgwick B., Riches K., Bageghni S.A., O'Regan D.J., Porter K.E., Turner N.A. Investigating inherent functional differences between human cardiac fibroblasts cultured from nondiabetic and Type 2 diabetic donors. Cardiovasc. Pathol. 2014, 23:204-210.
16. Hutchinson K.R., Lord C.K., West T.A., Stewart J.A. Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes. PLoS One 2013, 8:e72080.
17. Wang W.K., Lu Q.H., Zhang J.N., Wang B., Liu X.J., An F.S., Qin W.D., Chen X.Y., Dong W.Q., Zhang C., Zhang Y., Zhang M.X. HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway. J. Cell. Mol. Med. 2014, 18:2311-2320.
18. Song S.E., Kim Y.W., Kim J.Y., Lee D.H., Kim J.R., Park S.Y. IGFBP5 mediates high glucose-induced cardiac fibroblast activation. J. Mol. Endocrinol. 2013, 50:291-303.
19. Shamhart P.E., Luther D.J., Adapala R.K., Bryant J.E., Petersen K.A., Meszaros J.G., Thodeti C.K. Hyperglycemia enhances function and differentiation of adult rat cardiac fibroblasts. Can. J. Physiol. Pharmacol. 2014, 92:598-604.
20. Wang W.K., Wang B., Lu Q.H., Zhang W., Qin W.D., Liu X.J., Liu X.Q., An F.S., Zhang Y., Zhang M.X. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 2014, 172:202-212.
21. Mandavia C.H., Aroor A.R., Demarco V.G., Sowers J.R. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci. 2013, 92:601-608.
22. Kakkar R., Lee R.T. Intramyocardial fibroblast myocyte communication. Circ. Res. 2010, 106:47-57.
23. Pathak M., Sarkar S., Vellaichamy E., Sen S. Role of myocytes in myocardial collagen production. Hypertension 2001, 37:833-840.
24. Volz H.C., Seidel C., Laohachewin D., Kaya Z., Muller O.J., Pleger S.T., Lasitschka F., Bianchi M.E., Remppis A., Bierhaus A., Katus H.A., Andrassy M. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol. 2010, 105:805-820.
25. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
26. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Investig. 2007, 117:1538-1549.
27. Rui T., Zhang J., Xu X., Yao Y., Kao R., Martin C.M. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc. Res. 2012, 94:370-378.
28. Zhang W., Xu X., Kao R., Mele T., Kvietys P., Martin C.M., Rui T. Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation. PLoS One 2014, 9:e107639.
29. Rui T., Cepinskas G., Feng Q., Ho Y.S., Kvietys P.R. Cardiac myocytes exposed to anoxia-reoxygenation promote neutrophil transendothelial migration. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H440-H447.
30. Strutz F., Okada H., Lo C.W., Danoff T., Carone R.L., Tomaszewski J.E., Neilson E.G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 1995, 130:393-405.
31. Yao Y., Xu X., Zhang G., Zhang Y., Qian W., Rui T. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. Basic Res. Cardiol. 2012, 107:267.
32. Xu H., Su Z., Wu J., Yang M., Penninger J.M., Martin C.M., Kvietys P.R., Rui T. The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase gamma pathway. J. Immunol. 2010, 184:1492-1498.
33. Rajesh M., Mukhopadhyay P., Batkai S., Patel V., Saito K., Matsumoto S., Kashiwaya Y., Horvath B., Mukhopadhyay B., Becker L., Hasko G., Liaudet L., Wink D.A., Veves A., Mechoulam R., Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56:2115-2125.
34. Yang M., Wu J., Martin C.M., Kvietys P.R., Rui T. Important role of p38 MAP kinase/NF-{kappa}B signaling pathway in the sepsis-induced conversion of cardiac myocytes to a proinflammatory phenotype. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H994-H1001.
35. Fowlkes V., Clark J., Fix C., Law B.A., Morales M.O., Qiao X., ko-Asare K., Goldsmith J.G., Carver W., Murray D.B., Goldsmith E.C. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci. 2013, 92:669-676.
36. Broggi A., Granucci F. Microbe- and danger-induced inflammation. Mol. Immunol. 2015, 63:127-133.
37. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., Inoue K., Yamada S., Ijiri K., Matsunaga S., Nakajima T., Komiya S., Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48:971-981.
38. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., Buss S., Autschbach F., Pleger S.T., Lukic I.K., Bea F., Hardt S.E., Humpert P.M., Bianchi M.E., Mairbaurl H., Nawroth P.P., Remppis A., Katus H.A., Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
39. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., Ilyinskaya O., Tararak E., Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2320-2325.
40. Li L.C., Gao J., Li J. Emerging role of HMGB1 in fibrotic diseases. J. Cell. Mol. Med. 2014, 18:2331-2339.
41. Ma J., Chadban S.J., Zhao C.Y., Chen X., Kwan T., Panchapakesan U., Pollock C.A., Wu H. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 2014, 9:e97985.
42. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
43. Lin M., Tang S.C. Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol. Dial. Transplant. 2013, 4:746-754.
44. Andersson U., Antoine D.J., Tracey K.J. The functions of HMGB1 depend on molecular localization and post-translational modifications. J. Intern. Med. 2014, 276:420-424.
45. Villarreal D.O., Weiner D.B. IL-33 isoforms: their future as vaccine adjuvants?. Expert Rev. Vaccines 2015, 14:489-492.
46. Lopetuso L.R., Scaldaferri F., Pizarro T.T. Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 2012, 5:18.
47. Rankin A.L., Mumm J.B., Murphy E., Turner S., Yu N., McClanahan T.K., Bourne P.A., Pierce R.H., Kastelein R., Pflanz S. IL-33 induces IL-13-dependent cutaneous fibrosis. J. Immunol. 2010, 184:1526-1535.